The Risk Factors of Thrombosis in Complicated Arteriovenous Fistula
NCT ID: NCT05960877
Last Updated: 2023-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
69 participants
OBSERVATIONAL
2023-12-01
2025-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Arterio-Venous Fistula Audit. Successful Utilisation Rates of Arterio-Venous Fistulae for Haemodialysis at University Hospital Limerick
NCT05801549
av Fistula Patency Loss as a Cause of Fistula Failure and Hyperphosphatemia
NCT05569109
Clinical and Mechanistic Research on Autogenous Arteriovenous Fistula in Hemodialysis Patients
NCT07058441
Inflammatory Marker and Pre-existing Venous Fibrosis to Predict AVF Mal-maturation
NCT05136859
ENhancing Maturation of Autogenous Arteriovenous Hemodialysis Access by Aggressive surveillaNCe With Duplex and Endovascular Treatment
NCT01597115
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main renal replacement therapy was hemodialysis (HD) in 57% patients and peritoneal dialysis in 5% patients, while 37% patients underwent a functional kidney transplant.
Native arteriovenous fistula (AVF) is currently the best VA when technically feasible, according to the international dialysis guidelines.
Hemodialysis vascular access failure is the dominant cause of morbidity and the major cost of care for end-stage renal disease (ESRD) patients .
Complications such as thrombosis of VA remain the main problem for many patients with kidney failure.
Since 1994, prospective and case-control studies have explored the relationship between risk factors and arteriovenous fistula thrombus (AVFT) in patients undergoing HD .
Until now, these studies and reviews have revealed that numerous risk factors are associated with AVFT .
Risk factors like arterio-venous graft, age, female sex, C-reactive protein level, fistula site (distal), hypertension and the use of eprex can be associated with AVFT, and this knowledge advances the understanding of AVFT, facilitates multivariable risk prediction profiling, and lays the foundation for future preventive strategies .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Aldosouky
Resident doctor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Zhang Y, Yi J, Zhang R, Peng Y, Dong J, Sha L. Risk Factors for Arteriovenous Fistula Thrombus Development: A Systematic Review and Meta-Analysis. Kidney Blood Press Res. 2022;47(11):643-653. doi: 10.1159/000526768. Epub 2022 Sep 16.
Goldwasser P, Avram MM, Collier JT, Michel MA, Gusik SA, Mittman N. Correlates of vascular access occlusion in hemodialysis. Am J Kidney Dis. 1994 Nov;24(5):785-94. doi: 10.1016/s0272-6386(12)80672-x.
Fila B. Quality indicators of vascular access procedures for hemodialysis. Int Urol Nephrol. 2021 Mar;53(3):497-504. doi: 10.1007/s11255-020-02609-5. Epub 2020 Aug 31.
Fekih-Mrissa N, Sayeh A, Baffoun A, Beji M, Mrad M, Hmida J, Nsiri B. Association Between Thrombophilic Gene Mutations and the Risk of Vascular Access Thrombosis in Hemodialysis Patients. Ther Apher Dial. 2016 Apr;20(2):107-11. doi: 10.1111/1744-9987.12379. Epub 2016 Mar 23.
Vascular Access 2006 Work Group. Clinical practice guidelines for vascular access. Am J Kidney Dis. 2006 Jul;48 Suppl 1:S176-247. doi: 10.1053/j.ajkd.2006.04.029. No abstract available.
Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996 Apr;7(4):523-35. doi: 10.1681/ASN.V74523.
Salahi H, Fazelzadeh A, Mehdizadeh A, Razmkon A, Malek-Hosseini SA. Complications of arteriovenous fistula in dialysis patients. Transplant Proc. 2006 Jun;38(5):1261-4. doi: 10.1016/j.transproceed.2006.02.066.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AV fistula thrombosis
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.